Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial

NCT02765503 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 836

Last updated 2019-08-08

No results posted yet for this study

Summary

The aim of the study is to test whether a resource-sparing 4-week, 20-fraction course of accelerated hypofractionated radiotherapy is non-inferior to accelerated radiotherapy delivering 33 fractions over 5.5 weeks in the treatment of patients with Stage I-IV squamous cell carcinoma of the pharynx, larynx and oral cavity with the exception of paranasal sinus, nasopharyngeal and stage I-II glottic carcinomas.

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

RADIATION

External beam radiotherapy

External beam radiotherapy using megavoltage radiotherapy with radical intent.

Sponsors & Collaborators

  • Centro de Lucha contra el Cáncer, Montevideo, Uruguay

    collaborator UNKNOWN
  • Institute Rotary Cancer Hospital, New Delhi, India

    collaborator UNKNOWN
  • Tata Memorial Centre

    collaborator OTHER
  • Bahawalpur Institute of Nuclear Medicine and Oncology, Bahawalpur, Pakistan

    collaborator UNKNOWN
  • GKNM Hospital, Tamil Nadu, India

    collaborator UNKNOWN
  • Fundacion Escuela de Medicina Nuclear, Mendoza, Argentina

    collaborator UNKNOWN
  • Instituto de Oncología y Radiobiología, Havana, Cuba

    collaborator UNKNOWN
  • University of Indonesia, Jakarta, Indonesia

    collaborator UNKNOWN
  • St Luke's Medical Centre, Quezon City, Manilla, Phillippines

    collaborator UNKNOWN
  • University of Pretoria, Pretoria, South Africa

    collaborator UNKNOWN
  • Mahidol University

    collaborator OTHER
  • University of Maryland, College Park

    collaborator OTHER
  • Barretos Cancer Hospital, Barretos, Brazil

    collaborator UNKNOWN
  • International Atomic Energy Agency

    lead OTHER_GOV

Principal Investigators

  • Soren Bentzen · University of Maryland, College Park

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2020-11-30
Completion
2021-11-30

Countries

  • Argentina
  • Cuba
  • India
  • Indonesia
  • Pakistan
  • Philippines
  • South Africa
  • Thailand
  • Uruguay

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02765503 on ClinicalTrials.gov